OrbiMed Advisors Portfolio
13F Holdings & Position Changes — Last filed May 15, 2026
13F Holdings & Position Changes — Last filed May 15, 2026
One of the world's largest healthcare-dedicated investment firms, managing assets across public equity, private equity, royalties, and credit. OrbiMed's team of 100+ professionals includes physicians and PhDs covering all healthcare sub-sectors, with particular depth in biotech and pharma.
OrbiMed Advisors is a $19B biotech-focused hedge fund managed by Jonathan Silverstein (Executive Partner). As of their latest 13F filing (Q1 2026), the fund holds 98 positions worth $4.3B. This quarter they initiated 10 new positions and exited 113. Their largest holding is EWTX ($488.8M).
OrbiMed initiated 10 new positions and increased 32 this quarter. Portfolio shrank -9.0% to $4.3B. 1000 upcoming catalysts across holdings.
Portfolio Value (13F)
$4.3B
Holdings
98
Top 10 Concentration
45.4%
QoQ Change
-9.0%
Turnover
5.6%
Portfolio Value Trend
Be first to know when OrbiMed Advisors files next quarter
Get an email the moment new buys, exits, and conviction changes hit. Free 14-day trial.
| # | Ticker | Company | Change | Value | % of Portfolio | SI % Float ? | Trend |
|---|---|---|---|---|---|---|---|
| 1 | EWTX | Edgewise Therapeutics, Inc. | $488.8M | 11.45% | 13.1% | ||
| 2 | ELVN | Enliven Therapeutics, Inc. | $312.0M | 7.31% | 11.1% | ||
| 3 | LLY | Eli Lilly & Co | Decreased↓2Q | $217.8M | 5.10% | 1.1% | |
| 4 | SVA | Sinovac Biotech Ltd. | $184.5M | 4.32% | — | ||
| 5 | BSXOther Healthcare | Boston Scientific Corp. | Decreased↓5Q | $149.5M | 3.50% | 2.1% | |
| 6 | SION | Sionna Therapeutics, Inc. | Decreased↓2Q | $141.5M | 3.32% | 18.0% | |
| 7 | AZN | Astrazeneca Plc | New | $132.2M | 3.10% | 0.1% | — |
| 8 | MBX | MBX Biosciences, Inc. | Decreased↓2Q | $108.6M | 2.54% | 16.8% | |
| 9 | CRVS | Corvus Pharmaceuticals Inc. | $104.8M | 2.46% | 24.2% | ||
| 10 | ARGX | argenx SE | Decreased↓3Q | $100.0M | 2.34% | 3.3% |
Share changes reflect active decisions. Value changes include price moves.
Track this fund’s next move
13F changes, conviction shifts, and catalyst alerts across all 20 specialist biotech funds — free Monday brief.
See all 98 holdings (you're viewing the top 10), plus 6 quarters of position history.
No charge for 14 days · Cancel anytime
OrbiMed Advisors held 98 biotech stocks in their 13F portfolio this quarter. Their top positions include EWTX, ELVN, LLY, SVA, BSX. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
OrbiMed Advisors's tracked biotech portfolio is worth $4.3B across 98 positions, with total assets under management of approximately $19B. Portfolio values are based on 13F filings with the SEC.
OrbiMed Advisors initiated 10 new positions this quarter, including AZN, GH, STRO, DFTX, ALHC and 5 more. They also increased 32 existing positions.
OrbiMed Advisors fully exited 113 positions this quarter, including ITCI, IMVT, GERN, TXG, GHRS and 108 more. They also trimmed 33 existing positions.
One of the world's largest healthcare-dedicated investment firms, managing assets across public equity, private equity, royalties, and credit. OrbiMed's team of 100+ professionals includes physicians and PhDs covering all healthcare sub-sectors, with particular depth in biotech and pharma.
Track specialist biotech funds, insider signals, and AI analysis
Start 14-Day Free Trial